An Open Label, Multicenter Phase I/II Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Relapsed and/or Relapsed/Refractory Multiple Myeloma.

Trial Profile

An Open Label, Multicenter Phase I/II Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Relapsed and/or Relapsed/Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs P 276 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Biomarker
  • Sponsors Piramal Life Sciences
  • Most Recent Events

    • 28 Sep 2012 Status changed from recruiting to completed as reported by Clinical Trials Registry - India.
    • 09 Jun 2011 Planned End Date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 22 Jul 2009 New source identified and integrated (Clinical Trials Registry - India, CTRI2008-091-000004).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top